RET and non-small cell lung carcinoma: The National Comprehensive Cancer Network (NCCN) guideline for NSCLC (Version 1.2020) recommends targeted treatment for EGFR, ALK, ROS1, BRAF, NTRK, RET, HER2, MET amplification and exon 14 skipping mutation.